Zogenix

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.   We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Needle-Free Drug Injection Systems - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Needle-Free Drug Injection Systems is estimated at US$15.9 Billion in 2023 and is projected to reach US$29.9 Billion by 2030, growing at a CAGR of 9.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth of the needle-free drug injection system market is driven by multiple factors, including continuous technological innovations that enhance drug delivery mechanisms and device ergonomics. These advancements make the systems more efficient and user-friendly, fostering broader adoption. Stricter regulatory and safety standards aimed at reducing needlestick injuries and related liabilities also promote the shift towards needle-free systems. Healthcare worker advocacy and patient demand for less invasive treatment options further influence this trend, especially among individuals with needle aversions.

Needle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and Zogenix

BRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up to approximately US $1.9 billion / €1.7 billion*.

UCB Completes Acquisition of Zogenix, Inc.

EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

SAN DIEGO--(BUSINESS WIRE)-- #biotech--Immunicom adds Jennifer "J.D." Haldeman to its senior leadership team. Seasoned pharma executive becomes VP of Commercial Operations for the company.

Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates

EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the company is sponsoring a new no-cost genetic testing program, the United Mitochondrial Disease Foundation (UMDF) Pilot Genetic Testing Project, in partnership with UMDF and Probably Genetic, to help patients obtain a confirmed genetic diagnosis of mitochondrial disease. The program is available to any eligible patient in the U.S. with a suspected diagnosis of mitochondrial disease. Mitochondrial diseases are a group of rare, debilitating conditions that can severely impact daily living and quality of life, and are often fatal.5 , 6

Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases

The company attracts a determined suitor from abroad.

Why Zogenix Flew Higher Before Leveling Off This Week

AbbVie

Novavax

Pfizer

Valneva SE

Which biotech stocks are you watching today?

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist

Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?

NEW ORLEANS, Jan. 20, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

ZOGENIX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zogenix, Inc. - ZGNX

NEW YORK, Jan. 19, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX), in connection with the proposed acquisition of the Company by UCB S.A. ("UCB") (Euronext: UCB) via a tender offer.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Zogenix, Inc.

MILWAUKEE, Jan. 19, 2022 /PRNewswire/ -- Ademi LLP is investigating Zogenix (NASDAQ: ZGNX) for possible breaches of fiduciary duty and other violations of law in its transaction with UCB.  Click here to learn how to join the action: https://www.ademilaw.com/case/zogenix-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Zogenix, Inc. has obtained a Fair Price in its transaction with UCB.

Zogenix (NASDAQ:ZGNX), a global biopharma corporation that develops and commercializes therapies for rare medical conditions and diseases,shoots up 60% after it announced UCB would acquire it for roughly $1.9 billion.  According to the definitive agreement, UCB will acquire all of Zogenix's outstanding shares at a consideration of $26 per share in cash, plus a CVR (contingent […] The post Zogenix up 60% after being acquired by UCB appeared first on Invezz.

Zogenix up 60% after being acquired by UCB

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would acquire Zogenix for $26.00 per share in cash, plus a contingent value right for a potential cash payment of $2.00 per share upon EU approval by December 31, 2023, of FINTEPLA®. Halper Sadeh encourages Zogenix shareholders to click here to learn more about their legal r

Zogenix (ZGNX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Zogenix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ZGNX

Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. The post ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today appeared first on InvestorPlace.

ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today

A buyout deal is lighting a fire underneath the biotech's shares today.

Why Zogenix Stock Is on Fire Today

Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $1.9 billion. Under terms of the agreement, UCB will offer to purchase all outstanding shares of Zogenix for $26 per share in cash at closing.

Why Zogenix Shares Are Soaring Today

The stock price of Zogenix, Inc. (NASDAQ: ZGNX) increased by over 60% pre-market today. This is why it happened.

Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today

Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy. Investors will get $26 in cash for every Zogenix share, plus a potential $2 per share payment if Zogenix's Fintepla drug gets regulatory approval for Lennox-Gastaut syndrome by the end of 2023.

UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights

BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

UCB to acquire Zogenix

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA® (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome in Japan. FINTEPLA received Orphan Drug Designation from Japan's Ministry of Health, Labour & Welfare (MHLW) in August 2021.

Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA) for FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a highly treatment-resistant form of childhood-onset epilepsy. If approved, the application would expand the use of FINTEPLA in Europe beyond Dravet syndrome to include LGS.

Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

News for Zogenix Stock (ZGNX)